(BFLY) Butterfly Network, Inc. Company Overview

Butterfly Network, Inc. is a medical-technology and digital-health company listed on the New York Stock Exchange under BFLY. Its central idea is to replace the multiple specialized probes and bulky electronics of conventional ultrasound with a semiconductor-based, single-probe platform. The company combines portable hardware, cloud software, workflow tools, education, artificial intelligence, and licensing of its underlying Ultrasound-on-Chip technology. Butterfly’s stated mission is to make medical imaging more accessible, a strategy summarized on its official investor overview.

Which products define the platform?

The company still reports one operating segment, but its economics are no longer one-dimensional. The most useful analytical split is between the core imaging business and Embedded, and between product revenue recognized at delivery and software or service revenue recognized over time. That distinction explains both the growth opportunity and the volatility of quarterly margins.

Butterfly monetizes a common technology stack through several layers. First, it sells probes, carts, accessories, bladder systems, veterinary devices, and semiconductor chips. Second, it sells individual and enterprise software subscriptions, support, warranties, implementation, and integration. Third, it licenses SDKs and intellectual property and performs co-development work through Butterfly Embedded. The company’s FY2025 Form 10-K explains that device and perpetual SDK revenue is generally recognized at a point in time, while SaaS, warranties, term SDKs, and stand-ready services are recognized over time.

What did the Q1 2026 revenue mix look like?

Why does the mix matter more than unit growth alone?

Hardware expands the installed base, but recurring software and licensing can produce better incremental economics. In Q1 2026, product revenue grew only 3.5% year over year while software and other services grew 68.2%. The company explicitly expects profitability to improve as revenue shifts toward lower-delivery-cost software and services. However, Embedded revenue can be milestone-driven, partner-concentrated, and less linear than a conventional subscription model. A serious forecast therefore separates core device demand, recurring enterprise software, and partner licensing rather than applying one growth rate to total revenue.

The latest completed reporting period is the quarter ended March 31, 2026. Butterfly released those results on April 30, 2026 and filed its Form 10-Q. The official Q1 2026 earnings release showed a sharp improvement in revenue mix and gross margin, but the business remained loss-making and consumed cash.

How does the quarter compare with the annual trajectory?

Management reaffirmed FY2026 revenue guidance of $117M–$121M, implying approximately 20%–24% growth, and an adjusted EBITDA loss of $21M–$25M. That guidance is not the same as GAAP profitability, but it provides a useful scale target: revenue must continue compounding while the absolute cost base grows much more slowly.

Butterfly’s history matters because the company has repeatedly widened the scope of the same core invention. The strategic evolution is not simply a sequence of product launches; it is a transition from a handheld device company toward a software-defined ultrasound and sensing platform.

1. 2011
   Legacy Butterfly was founded. The foundational bet was that semiconductor manufacturing could digitize ultrasound transduction.
2. 2018
   Commercial launch of Butterfly iQ created a single-probe, whole-body handheld system and proved that the chip could support a real clinical product.
3. 2020–2021
   The second-generation iQ+ launched in 2020; the 2021 business combination brought public-market capital and the BFLY listing, while preserving the dual-class structure.
4. 2024
   iQ3 launched in the United States with higher pricing, stronger processing, and new 3D imaging tools. The company also introduced iQ+ Bladder as its first specialty product.
5. 2025
   Butterfly launched Compass AI, Butterfly Move, and iQ3 Vet; entered a major Embedded co-development and licensing agreement; and delivered its first positive operating-cash-flow quarter in Q4.
6. 2026
   Q1 software and service mix reached 44.8%, the Garden ecosystem reached 30 partners, and the company framed POCUS, Home & Community Care, and Embedded as three connected growth engines.

What changed when Butterfly moved beyond the probe?

The probe remains essential, but Compass AI and Butterfly Garden change the competitive unit from “device” to “platform.” Compass AI connects devices, departments, documentation, quality assurance, credentialing, billing workflows, and health-system infrastructure. Butterfly Garden gives external developers access to SDKs and APIs. Butterfly Embedded then takes the chip outside the company’s own end products. Each layer can deepen switching costs and increase revenue per installed device, but each also adds execution, cybersecurity, regulatory, and partner-management complexity.

Why is Ultrasound-on-Chip strategically different?

Butterfly’s principal differentiated resource is its capacitive micromachined ultrasonic transducer architecture. The official Ultrasound-on-Chip technology page describes thousands of CMUT elements integrated at wafer level, enabling a 1–12 MHz range from one probe. Conventional piezoelectric systems often require different probes for cardiac, abdominal, and vascular use. Butterfly’s architecture can emulate multiple array types in software, making the product compact, versatile, and upgradeable.

Who competes with Butterfly?

The moat is therefore not proven dominance. It is a resource-based advantage that combines proprietary chip design, a growing user base, clinical data, hardware-software integration, regulatory clearances, and enterprise workflow. The durability of that advantage depends on adoption, reliability, image quality, software execution, and the ability to convert technical differentiation into profitable recurring revenue.

Revenue growth alone can obscure whether Butterfly is becoming a scalable platform or merely selling more hardware. The strongest operating dashboard combines device adoption, mix, backlog-like obligations, enterprise penetration, and cash conversion.

Which mix indicators deserve the most attention?

Butterfly has substantial liquidity relative to its current operating scale, but it is not yet financially self-sustaining. At March 31, 2026, cash and equivalents were $138.0M, current assets were $239.8M, and current liabilities were $59.6M. The resulting current ratio was about 4.0 times. The company reported no floating-rate debt and expected existing resources to fund at least the next twelve months. These figures are detailed in the Q1 2026 Form 10-Q.

Why did FY2025 profitability look worse than the growth rate?

FY2025 revenue reached $97.6M, up 19.0%, but gross profit declined to $45.7M because the inventory and vendor-advance charge pushed cost of revenue to 53.1% of sales. Net loss was $77.1M. This is a reminder that hardware platform transitions can destroy accounting value even when demand improves. Q1 2026 gross margin of 68.9% suggests better underlying economics, but one quarter does not erase the inventory-control issue.

Economic ownership and voting control diverge sharply because Butterfly has two common-stock classes. Class A carries one vote per share; Class B carries twenty votes per share. The latest 2026 proxy statement reported 234.8 million Class A shares and 26.4 million Class B shares outstanding as of April 1, 2026.

How do incentives shape management priorities?

The 2025 annual bonus plan weighted revenue at 60%, adjusted EBITDA at 20%, and operational milestones at 20%. Those milestones included HomeCare progress, two additional Compass customers, the Compass 2.0 launch, and moving the P5-generation chip into production. This structure aligns management with growth and platform execution, but it also means researchers should distinguish compensation metrics from GAAP profitability and durable free cash flow.

Can enterprise software deepen the core economics?

Compass AI is designed to automate documentation, quality assurance, credentialing, workflow management, and revenue capture for point-of-care ultrasound programs. Butterfly’s official Compass AI page positions it as device-agnostic infrastructure that can ingest exams from Butterfly and non-Butterfly systems. If adoption grows, software could increase retention, expand departmental usage, and make the company less dependent on one-time probe sales.

Why could Embedded be transformational?

The Butterfly Embedded platform separates the value of the chip from Butterfly’s own device sales. Partners can license technology, pay for co-development, purchase chips, and potentially generate milestone or commercialization payments. Q1 2026 Embedded revenue of $5.7M already represented 21.6% of quarterly revenue. The upside is capital-light monetization and broader end markets; the risk is lumpy revenue, partner dependence, intellectual-property leakage, and long commercialization cycles.

Butterfly’s risk profile combines medical-device regulation, early-stage financial execution, manufacturing and inventory exposure, software and cybersecurity obligations, customer adoption, and concentrated voting control. The company’s opportunity is broad precisely because it is attempting several difficult transitions at once.

Which risk has the clearest financial evidence?

Inventory is the most visible recent example. Butterfly held $61.4M of inventory at December 31, 2025 and $59.3M at March 31, 2026, while FY2025 product revenue was $63.4M. That relationship reflects supply assurance and product breadth, but it also leaves the company exposed when a new chip, probe, or component makes prior stock less useful. The 2025 charge demonstrates that technological innovation can simultaneously strengthen the product and impair the balance sheet.

A conventional multiple based on current earnings is not informative because Butterfly remains unprofitable. A DCF or scenario analysis must instead model how three business engines mature: the core device and enterprise-software franchise, Home & Community Care, and Embedded licensing. The critical question is not whether revenue can grow for another year; it is whether the revenue mix can support positive operating cash flow before the liquidity cushion is materially depleted.

What should researchers monitor next?

• Q2 2026 revenue versus the company’s $27M–$31M guidance range and adjusted EBITDA loss versus $6M–$8M.
• Whether software and other services remain near or above the 44.8% Q1 mix without relying on one large milestone.
• Core revenue growth, international probe demand, veterinary adoption, and Compass AI enterprise deployments.
• Operating cash flow after Q1’s $13.9M use and the trajectory of cash from $138.0M.
• Inventory reductions, warranty reserve trends, and any new obsolescence charges during P5 and future chip transitions.
• New Embedded agreements, remaining performance obligations, partner concentration, and evidence of commercialization beyond co-development.
• Regulatory milestones for AI, home-care applications, and fourth-generation technology.
• The next reporting event: Butterfly has scheduled Q2 2026 results for July 30, 2026.

Butterfly Network matters because it has turned a semiconductor innovation into a commercially deployed whole-body ultrasound platform and is now trying to extend that platform into enterprise software, AI development, home care, veterinary applications, and third-party licensing. The company’s strongest evidence is the combination of 25% Q1 2026 revenue growth, 68.9% gross margin, a 44.8% software-and-services mix, $91.4M of remaining performance obligations, and a $138.0M liquidity base.

The weakness is equally specific: Butterfly still posted a $12.7M quarterly net loss, used $13.9M of operating cash in Q1, carries inventory close to one year of recent product revenue, and has already recorded large obsolescence charges. Its valuation story therefore depends on disciplined conversion, not technological novelty alone. Management must prove that core POCUS demand, Compass AI, and Embedded can grow together while reducing losses and avoiding repeated balance-sheet write-offs.